{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:47:18Z","timestamp":1791388038125,"version":"4.3.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01534-8","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T09:27:12Z","timestamp":1758878832000},"page":"3577-3592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Physician-Reported Treatment Patterns in Moderate to Severe Chronic Hand Eczema: the RWEAL Multinational Medical Chart Review"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5434-7753","authenticated-orcid":false,"given":"Ana","family":"Gim\u00e9nez-Arnau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1195-0290","authenticated-orcid":false,"given":"Anthony","family":"Bewley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3805-8219","authenticated-orcid":false,"given":"Christian","family":"Apfelbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7249-2556","authenticated-orcid":false,"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-2899","authenticated-orcid":false,"given":"Bleuenn","family":"Rault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9101-5636","authenticated-orcid":false,"given":"Alexanne","family":"Morillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5440-4436","authenticated-orcid":false,"given":"Douglas","family":"Maslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5402-1884","authenticated-orcid":false,"given":"Jenny M.","family":"Norlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9824-1034","authenticated-orcid":false,"given":"Marie-No\u00eblle","family":"Cr\u00e9py","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9383-034X","authenticated-orcid":false,"given":"Sonja","family":"Molin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"Suppl 1","key":"1534_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jdv.16061","volume":"34","author":"T Agner","year":"2020","unstructured":"Agner T, Elsner P. Hand eczema: epidemiology, prognosis and prevention. J Eur Acad Dermatol Venereol. 2020;34(Suppl 1):4\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"13","key":"1534_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134198","volume":"12","author":"A Zalewski","year":"2023","unstructured":"Zalewski A, Krajewski PK, Szepietowski JC. Prevalence and characteristics of itch and pain in patients suffering from chronic hand eczema. J Clin Med. 2023;12(13):4198.","journal-title":"J Clin Med"},{"issue":"5","key":"1534_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/cod.14035","volume":"86","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357\u201378.","journal-title":"Contact Dermatitis"},{"key":"1534_CR4","doi-asserted-by":"publisher","first-page":"adv00626","DOI":"10.2340\/actadv.v101.432","volume":"102","author":"AN Voorberg","year":"2022","unstructured":"Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and severity of hand eczema in the Dutch general population: a cross-sectional, questionnaire study within the lifelines cohort study. Acta Derm Venereol. 2022;102:adv00626.","journal-title":"Acta Derm Venereol"},{"key":"1534_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf020","author":"C Apfelbacher","year":"2025","unstructured":"Apfelbacher C, Bewley A, Molin S, Fargnoli MC, Gim\u00e9nez-Arnau AM, Brignoli L, et al. Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60,000 respondents in the general population in Canada, France, Germany, Italy, Spain, and the United Kingdom. Br J Dermatol. 2025. https:\/\/doi.org\/10.1093\/bjd\/ljaf020.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1534_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/cod.13113","volume":"80","author":"CJ Apfelbacher","year":"2019","unstructured":"Apfelbacher CJ, Ofenloch RF, Weisshaar E, et al. Chronic hand eczema in Germany: 5-year follow-up data from the CARPE registry. Contact Dermatitis. 2019;80(1):45\u201353.","journal-title":"Contact Dermatitis"},{"issue":"3","key":"1534_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14911","volume":"34","author":"S Ferrucci","year":"2021","unstructured":"Ferrucci S, Persichini P, Gola M, et al. DECISA project (DErmatology Clinics in Italy: Survey on Alitretinoin): a real-life retrospective cohort multicenter study on 438 subjects with chronic hand eczema. Dermatol Ther. 2021;34(3):e14911.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1534_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1684\/ejd.2022.4234","volume":"32","author":"D Lopez-Castillo","year":"2022","unstructured":"Lopez-Castillo D, Descalzo MA, Olmos-Alpiste F, et al. Chronic hand eczema: clinical characterization, aetiology, concomitant foot eczema and polysensitization. Eur J Dermatol. 2022;32(1):99\u2013106.","journal-title":"Eur J Dermatol"},{"key":"1534_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20140","author":"M Siewertsen","year":"2024","unstructured":"Siewertsen M, N\u00e4slund-Koch C, Duus Johansen J, et al. Psychological burden, anxiety, depression and quality of life in patients with hand eczema: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/jdv.20140.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10451","key":"1534_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","volume":"404","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Warren RB, Pinter A, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase\u00a03 trials. Lancet. 2024;404(10451):461\u201373.","journal-title":"Lancet"},{"key":"1534_CR11","unstructured":"European Medicines Agency. Anzupgo Summary of Product Characteristics. EMA, (2024). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/anzupgo-epar-product-information_en.pdf. Accessed Nov 2024."},{"issue":"4","key":"1534_CR12","first-page":"CD004055","volume":"4","author":"WA Christoffers","year":"2019","unstructured":"Christoffers WA, Coenraads PJ, Svensson \u00c5, et al. Interventions for hand eczema. Cochrane Database Syst Rev. 2019;4(4):CD004055.","journal-title":"Cochrane Database Syst Rev"},{"key":"1534_CR13","unstructured":"Fargnoli MC, Molin S, Bewley A, et al. The multifactorial and heterogenous nature of Chronic Hand Eczema in clinical practice: results from the RWEAL study. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024. Amsterdam, Netherlands. September 25\u201328, 2024. Abstract No. 4633. https:\/\/eadv.org\/wp-content\/uploads\/scientific-abstracts\/EADV-congress-2024\/Atopic-dermatitis-eczema.pdf. Accessed Aug 2025."},{"key":"1534_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdin.2023.11.004","volume":"14","author":"A Egeberg","year":"2023","unstructured":"Egeberg A, Schlapbach C, Haugaard JH, et al. Adverse events from topical corticosteroid use in chronic hand eczema - findings from the danish skin cohort. JAAD Int. 2023;14:77\u201383.","journal-title":"JAAD Int"},{"key":"1534_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1503","author":"MO Christensen","year":"2024","unstructured":"Christensen MO, Sieborg J, Nymand LK, et al. Prevalence and clinical impact of topical corticosteroid phobia among patients with chronic hand eczema-findings from the Danish skin cohort. J Am Acad Dermatol. 2024. https:\/\/doi.org\/10.1016\/j.jaad.2024.07.1503.","journal-title":"J Am Acad Dermatol"},{"issue":"4_suppl","key":"1534_CR16","doi-asserted-by":"publisher","first-page":"27S","DOI":"10.1177\/1203475419857668","volume":"23","author":"L Guenther","year":"2019","unstructured":"Guenther L, Lynde C, Poulin Y. Off-label use of topical calcineurin inhibitors in dermatologic disorders. J Cutan Med Surg. 2019;23(4_suppl):27S-34S.","journal-title":"J Cutan Med Surg"},{"key":"1534_CR17","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s13555-025-01433-y","volume":"15","author":"SA Mense","year":"2025","unstructured":"Mense SA, Maher S, Chovatiya R. A practical approach to chronic hand eczema. Dermatol Ther (Heidelb). 2025;15:1953\u201371.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1534_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/cod.14644","volume":"91","author":"FB Sedeh","year":"2024","unstructured":"Sedeh FB, Ullum AG, Christensen KB, et al. Reporting of self-reported hand eczema as an occupational disease in hospital cleaners: a cross-sectional questionnaire-based study. Contact Dermatitis. 2024;91:285\u201394.","journal-title":"Contact Dermatitis"},{"key":"1534_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2340\/00015555-1632","volume":"94","author":"C Apfelbacher","year":"2014","unstructured":"Apfelbacher C, Molin S, Weisshaar E, et al. Characteristics and provision of care in patients with chronic hand eczema: updated data from the CARPE registry. Acta Derm Venereol. 2014;94:163\u20137.","journal-title":"Acta Derm Venereol"},{"key":"1534_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/cod.14477","volume":"90","author":"E Borg","year":"2024","unstructured":"Borg E, Munro D, Thoning H. The management of chronic hand eczema: a retrospective patient record review. Contact Dermatitis. 2024;90:365\u201371.","journal-title":"Contact Dermatitis"},{"issue":"4","key":"1534_CR21","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/cod.14456","volume":"90","author":"MO Christensen","year":"2024","unstructured":"Christensen MO, Y\u00fcksel YT, Vittrup I, et al. Demographics, characteristics and medical treatment among adults with hand eczema in Denmark. a cross-sectional validation and registry-based study. Contact Dermatitis. 2024;90(4):350\u201364.","journal-title":"Contact Dermatitis"},{"issue":"3","key":"1534_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2340\/00015555-1256","volume":"92","author":"TL Diepgen","year":"2012","unstructured":"Diepgen TL, Pfarr E, Zimmermann T. Efficacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions: results of the TOCCATA open study comprising 680 patients. Acta Derm Venereol. 2012;92(3):251\u20135.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1534_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1684\/ejd.2018.3484","volume":"29","author":"B Halioua","year":"2019","unstructured":"Halioua B, Paul C, Berbis P, et al. Efficacy and safety of oral alitretinoin as treatment for chronic hand eczema in France: a real-life open-label study. Eur J Dermatol. 2019;29(1):59\u201366.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"1534_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/jdv.20490","volume":"39","author":"MA Lef\u00e8vre","year":"2025","unstructured":"Lef\u00e8vre MA, Tauber M. Alitretinoin is not a suitable treatment for the majority of chronic hand eczema patients. J Eur Acad Dermatol Venereol. 2025;39(2):261\u20132.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1534_CR25","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1111\/jdv.20165","volume":"39","author":"ATM R\u00f8nnstad","year":"2025","unstructured":"R\u00f8nnstad ATM, Nielsen ML, Schlapbach C, et al. Drug survival of alitretinoin treatment for chronic hand eczema: a Danish nationwide cohort study. J Eur Acad Dermatol Venereol. 2025;39(2):e118\u201321.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1534_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/cod.14699","volume":"92","author":"YT Y\u00fcksel","year":"2025","unstructured":"Y\u00fcksel YT, Thoning H, Larsen LS, et al. Evaluation of validity, reliability and ability to detect change for the hand eczema severity index (HECSI) and evaluation of HECSI-75 and HECSI-90 as within-patient responder definitions. Contact Dermatitis. 2025;92:51\u201360.","journal-title":"Contact Dermatitis"},{"key":"1534_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20671","author":"H R\u00f6nsch","year":"2025","unstructured":"R\u00f6nsch H, Drewitz KP, Atwater AR, et al. Consensus on core domains for hand eczema trials: signs, symptoms, control and quality of life. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.20671.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1534_CR28","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/S0140-6736(25)00001-7","volume":"405","author":"AM Gim\u00e9nez-Arnau","year":"2025","unstructured":"Gim\u00e9nez-Arnau AM, Pinter A, Sondermann W, et al. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase\u00a03 trial. Lancet. 2025;405:1676\u201388.","journal-title":"Lancet"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01534-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01534-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01534-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:22:07Z","timestamp":1763198527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01534-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1534"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01534-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ana Gim\u00e9nez-Arnau has received research or advisory funding from Almirall, Amgen, AstraZeneca, Avene, Celldex, Celltrion, Escient Pharmaceuticals, Genentech, GSK, Instituto Carlos III- FEDER, LEO Pharma, Menarini, Mitsubishi Tanabe Pharma, Novartis Sanofi\u2013Regeneron, Servier, Thermo Fisher Scientific, Uriach Pharma \/ Noucor. Anthony Bewley has had ad hoc consultancy\/travel\/lecturing agreements with AbbVie, Almirall, BMS, Galderma, Janssen Pharmaceuticals, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi and UCB. Christian Apfelbacher has received honoraria for consultancy work from Dr Wolff GmbH Bionorica, Sanofi, LEO Pharma, Incyte, Pfizer, Rheacell and IVDK and institutional funding from Dr Wolff GmbH and Bionorica. Maria Concetta Fargnoli has received honoraria or grants from Amgen, Almirall, Abbvie, Boehringer Ingelheim, BMS, Galderma, Kyowa Kyrin, Incyte, LEO Pharma, Pierre Fabre, UCB, Lilly, Pfizer, Janssen, MSD, Novartis, Sanofi, Regeneron, Sun Pharma, Takeda. Marie-No\u00eblle Cr\u00e9py has been a consultant, advisory board member, investigator, and\/or speaker for AbbVie, LEO Pharma, Pfizer, and Sanofi Genzyme. Sonja Molin has been an investigator and\/or has received honoraria as consultant\/advisor or speaker and\/or grants from Abbvie, Almirall, Alumis, Aralez, Arcutis, Basilea, Bausch and Lomb, Bristol Myer Squibb, Boehringer Ingelheim, Evidera, Galderma, GSK, Incyte, Jamp Biopharma, Janssen, LEO Pharma A\/S, Lilly, Moonlake, Novartis, Pfizer, Sanofi, Sun Pharma, and UCB. Bleuenn Rault and Alexanne Morillo are employees of Oracle Life Sciences. Douglas Maslin and Jenny M. Norlin are employees and shareholders of LEO Pharma A\/S.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"No personal identifiable information of physicians or patients were recorded. All physicians provided informed consent to proceed with the study. The research was approved by the Cerner Enviza Independent Review Board (IRB) for ethical review (Number 0018).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}